Bristol Myers Squibb Vanlev
Executive Summary
FDA's Cardiovascular and Renal Drugs Advisory Committee will review omapatrilat for hypertension May 1 at 8:30 a.m. at NIH's Masur Auditorium in Bethesda, Md. The committee will also review King's Altace (1"The Pink Sheet" March 13, In Brief)